File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Consensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong

TitleConsensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong
Authors
Keywordsaripiprazole
consensus statement
Hong Kong
Issue Date2020
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1445-5994
Citation
Internal Medicine Journal, 2020, v. 50 n. S3, p. 6-14 How to Cite?
AbstractAripiprazole, a dopamine partial agonist, is a second‐generation anti‐psychotic that is widely used for the treatment of schizophrenia and other psychotic disorders. A group of psychiatric experts in Hong Kong developed a set of consensus statements, aiming to facilitate the understanding of clinical properties and usages of aripiprazole among local physicians. Of note, because aripiprazole long‐acting injectable has been available locally not long before the establishment of the consensus panel, which limited the discussion on its use in the local context, the consensus statements were focused primarily on oral aripiprazole. To draft the consensus statements, the panellists discussed the published evidence and their clinical experience regarding aripiprazole in a series of meetings based on several areas. At the final meeting, each drafted statement was voted on anonymously by all panellists based on its practicability of recommendation in Hong Kong. A set of consensus statements on the characteristics and clinical use of aripiprazole was established and accepted by the panel. These statements serve to provide a practical reference for physicians in Hong Kong, and possibly other parts of the Asia‐Pacific region, on the use of aripiprazole in people with schizophrenia spectrum disorders and other psychotic problems.
Persistent Identifierhttp://hdl.handle.net/10722/288151
ISSN
2019 Impact Factor: 1.677
2015 SCImago Journal Rankings: 0.616

 

DC FieldValueLanguage
dc.contributor.authorWong, MMC-
dc.contributor.authorChung, AKK-
dc.contributor.authorYeung, TMH-
dc.contributor.authorWong, DTW-
dc.contributor.authorLee, CK-
dc.contributor.authorLai, E-
dc.contributor.authorChan, GFY-
dc.contributor.authorMak, GKL-
dc.contributor.authorWong, JOY-
dc.contributor.authorNg, RMK-
dc.contributor.authorTam, KL-
dc.contributor.authorMak, KY-
dc.date.accessioned2020-10-05T12:08:37Z-
dc.date.available2020-10-05T12:08:37Z-
dc.date.issued2020-
dc.identifier.citationInternal Medicine Journal, 2020, v. 50 n. S3, p. 6-14-
dc.identifier.issn1444-0903-
dc.identifier.urihttp://hdl.handle.net/10722/288151-
dc.description.abstractAripiprazole, a dopamine partial agonist, is a second‐generation anti‐psychotic that is widely used for the treatment of schizophrenia and other psychotic disorders. A group of psychiatric experts in Hong Kong developed a set of consensus statements, aiming to facilitate the understanding of clinical properties and usages of aripiprazole among local physicians. Of note, because aripiprazole long‐acting injectable has been available locally not long before the establishment of the consensus panel, which limited the discussion on its use in the local context, the consensus statements were focused primarily on oral aripiprazole. To draft the consensus statements, the panellists discussed the published evidence and their clinical experience regarding aripiprazole in a series of meetings based on several areas. At the final meeting, each drafted statement was voted on anonymously by all panellists based on its practicability of recommendation in Hong Kong. A set of consensus statements on the characteristics and clinical use of aripiprazole was established and accepted by the panel. These statements serve to provide a practical reference for physicians in Hong Kong, and possibly other parts of the Asia‐Pacific region, on the use of aripiprazole in people with schizophrenia spectrum disorders and other psychotic problems.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1445-5994-
dc.relation.ispartofInternal Medicine Journal-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectaripiprazole-
dc.subjectconsensus statement-
dc.subjectHong Kong-
dc.titleConsensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong-
dc.typeArticle-
dc.identifier.emailWong, MMC: mmcwong@hkucc.hku.hk-
dc.identifier.emailChung, AKK: chungkka@hku.hk-
dc.identifier.emailLee, CK: leekryst@hku.hk-
dc.identifier.emailLai, E: eric86@hku.hk-
dc.identifier.emailMak, GKL: mkl737@hku.hk-
dc.identifier.emailWong, JOY: wongoyj@hku.hk-
dc.identifier.emailNg, RMK: rmkng@hkucc.hku.hk-
dc.identifier.emailTam, KL: tamklb@hku.hk-
dc.identifier.authorityChung, AKK=rp02341-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/imj.14896-
dc.identifier.pmid32985093-
dc.identifier.scopuseid_2-s2.0-85091506014-
dc.identifier.hkuros315663-
dc.identifier.volume50-
dc.identifier.issueS3-
dc.identifier.spage6-
dc.identifier.epage14-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats